目的：研究鲨鱼口服液对15名2型糖尿病病人短期病情控制、症状影响。方法：采用单盲、交叉对照等方法，对鲨鱼口服液受试者的血、尿常规，生化指标、血糖及糖化血清蛋白，以及临床症状等指标进行考察，观察时间为20 d。结果：患者在服用鲨鱼口服液可能改善糖尿病的症状，试验前10.7±6.4分，服用口服液后降为5.8±5.3，与安慰剂对比（P<0.05）。同时该试验品对糖尿病患者的肝、肾、心脏功能及血液学功能等无明显不良影响。结论：鲨鱼口服液在2型糖.尿病患者短期应用安全、可能改善症状、应用简便，但对血糖的影响仍需要长期观察。

Background The etiologic agent of severe acute re spiratory syndrome (SARS) ha s been confirmed to be a novel coronavirus (CoV), namely SARS2CoV1 Developing safe and effective SARS2CoV vaccine s is e ssential for us to prevent the po ssible reemergence of it s epidemic1 Previous experience s indicate that inactivated vaccine is conventional and more hopeful to be succe ssfully developed1 Immunogenicity evaluation of an experimental inactivated SARS2CoV vaccine in rabbit s wa s conducted and reported in this paper1 Methods The large2scale cultured SARS2CoV F69 strain wa s inactivated with 014 % formaldehyde and purified, then used a s the immunogen combined with Freund’s adjuvant1 Eight adult New Zealand rabbit s were immunized four time s with this experimental inactivated vaccine1 Twelve set s of rabbit serum were sampled from the third day to the seventy2fourth day after the first vaccination1 The titers of specific anti-SARS2CoV IgG antibody were determined by indirect enzyme2linked immuno sorbent a ssay, and the neutralizing antibody titers were detected with micro2cytopathic effect neutralization te st1 Results Rapid and potent humoral immune re sponse s were induced by the inactivated SARS2CoV vaccine in all the eight te st rabbit s1 Titers of both specific IgG antibody and neutralizing antibody peaked at about six weeks after first vaccination, with the maximum value of 1∶81 920 and 1∶20 480,re spectively1 After that, serum antibody levels remained at a plateau or had a slight decrea se, though two boo sters were given in the succedent 4 to 5 weeks1 Cro ss neutralization re sponse existed between SARS2CoV F69 strain and Z22Y3 strain1 Co ncl us i o ns The inactivated SARS2CoV vaccine made from F69 strain owns strong immunogenicity, and the cro ss neutralization re sponse between the two different SARS2CoV strains give s a hint of the similar neutralizing epitope s, which provide stable ba se s for the development of inactivated SARS2 CoV vaccine s1

目的：研究重组工程菌的遗传稳定性。方法：利用重组表达质粒pBVNM-HI转化宿主菌E.coli DI-LSa，筛选重组工程菌DH5a-pBVNM-HI。将新构建好的重组工程菌在无选择压力的条件下进行连续传代培养，比较菌落在LB（-）和LB（+）培养基上的生长状况，并对传代菌株目标蛋白的表达情况以及质粒数量和目的基因DNA进行电泳鉴定。结果：重组工程菌连续传代5O次中，在LB（-）和LB（+）培养基上的生长状况相同，目标蛋白表达量无显著差异，质粒数量及目的基因DNA结构稳定。结论：重组工程菌DH5a-pBVNM.HI具有良好的遗传稳定性。

为制备纯化的灭活SARS病毒，取广东省CDC提供的灭活SARS-CoV病谳培养液进行超滤，收集相对分子质量介于100000至500000之间的组分。并浓缩。对纯化过程中各组分进行抗原活性签定和蛋白质含量测定。并加佐剂后免疫动物，测定抗体免疫应答。结果表明：超滤后活性抗原蛋白质回收率7.6%，纯化倍数为9，抗原活性达到1∶480 免疫家免获得的血清ELISA效价达到1∶10000以上，中和抗体效价达到1∶2000以上。表明该纯化工艺能获得较高纯度的灭活SARS-CoV病毒颗粒。

目的 研究重组人源抗HBsAg单链抗体（HBscFv）在HBV转基因小鼠体内的活性作用，探讨HBV转基因小鼠作为HBsAg特异性抗体的结合活性评价模型的可行性。方法 工程菌表达的HBscFv包涵体经固定化金属螯合层析和分子排阻层析两步纯化后，分步透析复性。复性后的HBscFv（0.9g/L）经尾静脉注射HBV转基因小鼠，一定时间后测定鼠血清中HBsAg的浓度，计算抗体注射前后HBsAg浓度下降的百分比（结合率），同时以人血源HBsAb IgG（40U/ml）和生理盐水作为对照。结果 两步纯化获得纯度达到98%的重组HBscFv。HBscFv制品能够结合转基因小鼠体内的HBsAg，其结合率为（30.47±9.85）%，与生理盐水组差异有显著性（P<0.001），与HBsAb IgG组差异无显著性（P>0.05）；对照品HBsAb IsG的结合率为（39.00±7.43）%，与生理盐水组差异也有显著性（P<0.001）。比较HBscFv和HBsAb IgG的结合率及其浓度，求得HBscFv的结合效价为31.58U/mg。结论 HBscFv在转基因小鼠体内具有特异性结合HBsAg活性，HBV转基因小鼠可发展为评价HBsAs特异性抗体的体内结合活性的候选模型。